Testing QL2109 with daratumumab for advanced multiple myeloma
Treatments studied
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This trial is testing a new drug called QL2109 combined with Darzalex Faspro (daratumumab and hyaluronidase) for people with multiple myeloma that has returned or not responded to earlier treatments. The goal is to see if this combination can better control the cancer compared to standard options.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old.
- Your multiple myeloma can be measured with a blood or urine test (or a specific light chain test).
- You have already had at least one prior treatment, and that treatment included both a proteasome inhibitor (like bortezomib) and lenalidomide.
- Your disease has gotten worse on or after your last treatment.
- You are able to do most daily activities (ECOG performance status 0–2).
- Your blood counts, liver function, kidney function, and calcium levels are within the required ranges.
- You have not previously taken pomalidomide or any anti-CD38 antibody (like daratumumab).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study compares a new experimental drug called QL2109 with an approved treatment called daratumumab in healthy male volunteers. It is a first-in-human trial, which means the drug is being tested in people for the first time.
This trial tests two different drug combinations for people newly diagnosed with multiple myeloma who are not getting a stem cell transplant right away. It compares one drug (elranatamab) to another (daratumumab), both given with a standard three-drug regimen called RVd Lite, to see which works better.
This trial tests a new medicine (GR1803) against a standard combination treatment for people whose multiple myeloma has come back or stopped responding to prior therapies. It aims to see if the new drug works better.
This trial tests a combination of two drugs, daratumumab and lenalidomide, for patients with multiple myeloma that has not responded to previous treatments. It aims to see if this regimen can help when other therapies have stopped working.
This trial tests different dosing schedules of daratumumab to find a more cost-effective option for patients with multiple myeloma who have already had a stem cell transplant and achieved at least a partial response. It aims to see if a lower dose can work just as well.
This trial tests a new combination of four drugs for people with high-risk multiple myeloma that has come back or did not respond to initial treatment. The goal is to see if this combination is safe and effective.
Hear when a new Multiple myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.